True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study

International Journal of Gynecological Pathology

Volumn 29, Issue 3, 2010, Pages 282-289

  Hsu, Jeng Dong ^a,e   Yao, Chung Chin ^c   Lee, Ming Yung ^f   Kok, Lai Fong ^g   Wang, Po Hui ^a   Tyan, Yeu Sheng ^a,e   Han, Chin Ping ^a,b,d,e  

^a Department of Obstetrics and Gynecology ^*  (United States)

^b Clinical Trials Center   (United States)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Institute of Medicine   (United States)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f Providence University   (United States)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CAM 5.2; CK8 18; Cytokeratin; Endocervical adenocarcinomas; Endometrial adenocarcinomas; Hematoxylin and eosin; Immunohistochemistry; Tissue microarray

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8;

ARTICLE; ENDOCERVICAL ADENOCARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAIWAN; TISSUE MICROARRAY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; KERATIN-8; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; UTERINE CERVICAL NEOPLASMS;

EID: 77951730351     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181c043bc     Document Type: Article

References (32)

1. Lurain JR, Bidus MA, Elkas JC. Uterine cancer, cervical and vaginal cancer. In: Berek RS, ed. Novak's Gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:1343-1402.
2. Schorge JO, Knowles LM, Lea JS. Adenocarcinoma of the cervix. Curr Treat Options Oncol 2004;5:119-127
3. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003;442:271-277
4. Becton Dickinson. Anti-Cytokeratin (CAM 5.2) Reagent For In Vitro Diagnostic Use 50 Tests per Vial, Catalog No. 349205, 9/97, 23-3190-01, and Material Safety Data Sheet, acc. to ISO/ DIS 11014. 1997. Available at: http://www.bdbiosciences.com/pt Product.jsp?prodId=22700 and http://www.bdbiosciences.com/ external-files/is/doc/msds/live/web-enabled/ 349205-MSDS-US EN.A.pdf. Accessed December 31, 2009.
5. Bondt Ready-To-Use Primary Antibody, Cytokeratin 8/18 (5D3) 2008 Catalog No: PA0067. Available at: http://bsd.leicamicrosystems. com/pdfs/products/ pa0067.pdf Accessed December 31, 2009.
6. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577
7. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283-298
8. Yao CC, Kok LF, Lee MY, et al. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet 2009;280:405-413
9. Han CP, Kok LF, Wang PW, et al. Scoring p16INK4a immunohistochemistry based on independent nucleic staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol 2009;22:797-806.
10. Han CP, Lee MY, Tzeng SL, et al. Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res 2008;27:25.
11. Dabbs DJ, Sturtz K, Zaino RJ, et al. Distinguishing endometrial from endocervical adenocarcinoma. Hum Pathol 1996;27:72-77
12. Castrillon DH, Lee KR, Nucci MR, et al. Distinction between endometrial and endocervical adenocarcinoma: An immunohistochemical study. Int J Gynecol Pathol 1996;21:4-10.
13. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002;21:11-15.
14. Liao CL, Lee MY, Tyan YS, et al. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J Transl Med 2009;7:37.
15. Koo CL, Kok LF, Lee MY, et al. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 2009;7:25.
16. Han CP, LeeMY, Kok LF, et al. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol 2009;28:489-496
17. Wehling M. Translational medicine: science or wishful thinking? J Transl Med 2008;6:31.
18. Kamoi S, AlJuboury MI, Akin MR, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: Another viewpoint. Int J Gynecol Pathol 2002;21:217-223
19. Khoury T, Tan D, Wang J, et al. Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma. BMC Clin Pathol 2006;6:1.
20. Reid-Nicholson M, Iyengar P, Hummer AJ. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006;19:1091-1100. Epub April 28, 2006.
21. Fregonesi PA, Teresa DB, Duarte RA, et al. p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 2003;51:1291-1297
22. Vallmanya LFR, Laborda RA, Lloreta TJ, et al. Immunohistochemical expression of p53, p21, p16, and cyclin D1 in superficial bladder cancer. A tissue microarray study. Actas Urol Esp 2006;30:754-762
23. Kok LF, Lee MY, Tyan YS, et al. Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet 2010;281:293-300.
24. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003;22:231-235
25. Milde-Langosch K, Bamberger AM, Rieck G. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001;67:61-70.
26. McCluggage WG. Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int J Gynecol Pathol 2006;25:101-120
27. Yemelyanova A, Vang R, Seidman JD, et al. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol 2009;33:914-924
28. Han CP, Lee MY, Tyan YS, et al. p16(INK4) and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16(INK4)) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study. Virchows Arch 2009:455:353-361
29. Jaworski RC, Roberts JM, Robboy SJ, et al. Cervical glandular neoplasia. In: Robboy's, ed. Pathology of the Female Reproductive Tract. 2nd ed. Philadelphia: Churchill Livingstone, Elsevier Science; 2009:249-279
30. Young RH, Clement PB. Pathology of endometrial carcinoma. In: Fuller AF, Seiden MV, Young RH, American Cancer Society, eds. Uterine Cancer. 1st ed. Ontario: PMPH USA; 2004:52-77.
31. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002;41:185-207.
32. Han CP, Kok LF, Lee MY, et al. Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. Arch Gynecol Obstet 2010;281:317-323